Pre-Stem Cell Transplant Treatment Regimen for AML, MDS - NCI

July 05,2024

A Cancer Currents blog on a study suggesting that an intensive preparatory regimen should be used for younger patients with AML undergoing a stem cell transplant.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation - Biology of Blood and Marrow Transplantation

Cancers, Free Full-Text

A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies

Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf

Frontiers Low-Dose Decitabine Monotherapy Reverses Mixed Chimerism in Adult Patients After Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimen: A Pilot Phase II Study

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation

Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis, BMC Cancer

Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy, Molecular Cancer

Full article: Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis